Xu Yuan 4

What Happened
Xu Yuan, a director of Xilio Therapeutics (XLO), was granted a derivative award for 5,000 shares on June 11, 2026. The Form 4 reports the transaction as an award/grant (code A) at $0.00 per share (total reported value $0). The award will vest 100% on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to Xu’s continued service.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (filed next day; appears timely).
• Transaction type: Award/Grant of a derivative security (options or similar) — 5,000 underlying shares.
• Reported price/value: $0.00 per share; total reported $0 (derivative grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Vesting — 100% vests on earlier of (i) 6/11/2027 or (ii) the issuer’s next annual meeting, contingent on continued service.
• No exercise or sale occurred — this is a grant, not a purchase or disposition.

Context
This filing documents a compensation-related option/award to a director rather than market buying or selling. Such grants give the holder the right to acquire shares in the future subject to vesting and any exercise terms; the filing does not show an exercise price or any immediate share sale. Grants to directors are common as part of non-cash compensation and do not by themselves indicate an intent to buy or sell stock in the market.